Nektar Therapeutics Cash Flow - Quarterly (NASDAQ:NKTR)

Add to My Stocks
$22.24 $0.07 (0.32%) NKTR stock closing price Jul 21, 2017 (Closing)

The Nektar Therapeutics cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. The profit-loss statement shows Nektar Therapeutics profits, the balance sheet shows Nektar Therapeutics debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. The cash flow statement is essetial while conducting the Nektar Therapeutics cash flow analysis and can be used to measure the operating performance of Nektar Therapeutics compared to various industry peers like AVNR stock and WX stock. Nektar Therapeutics saw a inflow of $69.33M from investing activities for 2017-Q1. View details of Nektar Therapeutics cash flows for latest & last 40 quarters.

show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4
Nektar Therapeutics Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow4.03M15.35M11.5M7.63M3.71M12.85M9.1M5.83M2.97M12.92M
Net Increase (Decrease) in Assets Liabilities19.92M7.93M26.01M16.47M-12.12M-34.7M6.23M18.44M21.19M-116.42M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net5.34M13.21M9.19M6.74M4.25M29.94M13.72M10.61M5.32M15.4M
Nektar Therapeutics Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-4.08M-6.39M-3.74M-3.23M-1.67M-11.19M-8.72M-4.58M-1.05M-9.97M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments-8.98M-76M63.44M34.55M37.92M-28.14M-23.4M-8.25M54.21M-27.59M
Other Cash Inflow (Outflow) from Investment Activities-----25M25M---
Nektar Therapeutics Net Cash from (used by) Invesment Activities
Issuance (Purchase) of Equity Shares11.79M209.56M18.04M9.64M6.09M32.2M15.51M7.79M1.68M163.52M
Issuance (Repayment) of Debt Securities-0.61M-5.94M-5.37M-3.51M-1.72M98.57M-3.79M-2.48M-1.09M-3.53M
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------7M
Nektar Therapeutics Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash0.29M-0.12M-0.03M-0.09M0.01M-0.15M-0.15M-0.02M0.03M-0.1M
Nektar Therapeutics Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year55.57M12.36M39.06M25.43M15.31M17.75M49.59M155.58M76.29M63.76M
Cash & Equivalents at Year End23.48M59.64M63.29M55.67M72.54M55.57M18.81M20.87M129.45M12.36M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Cash flow for another ticker

Nektar Therapeutics stock price history provides insight into historical stock price fluctuations, and Nektar Therapeutics stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:
  • Net Change in Cash and Cash Equivalents: Nektar Therapeutics cash grew QoQ to $-63.86M, meaning the company is able to meet its expenditure and grow cash which will also eventually reflect in the Nektar Therapeutics stock price movement.
  • Cash Flow from operating activities: Nektar Therapeutics reported a negative operating cash flow of $-34.56M for 2017-Q1 and has seen an increase from the previous quarter. Operating cash flow or working capital comes from main business activities. Investors look for positive cash flow from recurring operating activities.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc. , and was $-34.56M for NKTR in last quarter report.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $11.17M for Nektar Therapeutics.

Key Financial Ratios For Nektar Therapeutics Cash Flow

FCF margin